edoc

Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes

Kuemmerle-Deschner, Jasmin B. and Hachulla, E. and Cartwright, R. and Hawkins, P. N. and Tran, T. A. and Bader-Meunier, B. and Hoyer, J. and Gattorno, M. and Gul, A. and Smith, J. and Leslie, K. S. and Jiménez, S. and Morell-Dubois, S. and Davis, N. and Patel, N. and Widmer, A. and Preiss, R. and Lachmann, H. J.. (2011) Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Annals of the rheumatic diseases : ARD, Vol. 70, H. 12. pp. 2095-2102.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6004036

Downloads: Statistics Overview

Abstract

Longer-term effects of prolonged selective interleukin-1? blockade with canakinumab were evaluated in the largest cohort of cryopyrin-associated periodic syndrome (CAPS) patients studied to date.
Faculties and Departments:03 Faculty of Medicine > Bereich Medizinische Fächer (Klinik) > Infektiologie > Infektiologie (Battegay M)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Medizinische Fächer (Klinik) > Infektiologie > Infektiologie (Battegay M)
UniBasel Contributors:Widmer, Andreas F.-X.
Item Type:Article, refereed
Article Subtype:Research Article
Bibsysno:Link to catalogue
Publisher:British Medical Association
ISSN:0003-4967
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:27 Mar 2014 13:13
Deposited On:27 Mar 2014 13:13

Repository Staff Only: item control page